Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase.
Fiche publication
Date publication
juin 2023
Journal
Antimicrobial agents and chemotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RUFF Marc
Tous les auteurs :
Bonnard D, Le Rouzic E, Singer MR, Yu Z, Le Strat F, Batisse C, Batisse J, Amadori C, Chasset S, Pye VE, Emiliani S, Ledoussal B, Ruff M, Moreau F, Cherepanov P, Benarous R
Lien Pubmed
Résumé
HIV-1 integrase-LEDGF allosteric inhibitors (INLAIs) share the binding site on the viral protein with the host factor LEDGF/p75. These small molecules act as molecular glues promoting hyper-multimerization of HIV-1 IN protein to severely perturb maturation of viral particles. Herein, we describe a new series of INLAIs based on a benzene scaffold that display antiviral activity in the single digit nanomolar range. Akin to other compounds of this class, the INLAIs predominantly inhibit the late stages of HIV-1 replication. A series of high-resolution crystal structures revealed how these small molecules engage the catalytic core and the C-terminal domains of HIV-1 IN. No antagonism was observed between our lead INLAI compound BDM-2 and a panel of 16 clinical antiretrovirals. Moreover, we show that compounds retained high antiviral activity against HIV-1 variants resistant to IN strand transfer inhibitors and other classes of antiretroviral drugs. The virologic profile of BDM-2 and the recently completed single ascending dose phase I trial (ClinicalTrials.gov identifier: NCT03634085) warrant further clinical investigation for use in combination with other antiretroviral drugs. Moreover, our results suggest routes for further improvement of this emerging drug class.
Mots clés
ALLINI, HIV-1, LEDGF, allosteric inhibitor, antiretrovirals, cocrystallization., drug discovery, integrase, integrase inhibitor, molecular glue, protein-protein interaction inhibitor
Référence
Antimicrob Agents Chemother. 2023 06 13;:e0046223